Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Recruiting
Phase 3
Interventional Study
Brain Injuries
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- Up to 18
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Children with traumatic brain injury: Moderate and Severe.
Exclusion Criteria:
* Underlying CNS disorders,
Contacts